Diamyd Staves Off Liquidation, Returns Cash to Shareholders

Following pressure from a group of dissident shareholders, Diamyd Medical AB agreed to return most of its cash to its investors, while retaining a small amount to continue two Phase II trials of its GAD vaccine for the treatment and prevention of Type I diabetes.

To continue reading subscribe now to BioWorld Asia (formerly International)